RxDoctor Payments Data

Clyde Moreland, MD

Internal Medicine · St Petersburg, FLNPI 1174569123

Payments from drug & device makers

$4,187in general payments, 2019–2025

Across 194 payments — averaging $21.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$2K
  • Viiv Healthcare Company$1K
  • Merck$192
  • Exact Sciences$96
  • Hologic Sales And Service, LLC$86
  • Theratechnologies Inc.$52
  • plus $230 from 10 others

What the payments were for

  • Food & beverage$4,187100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,187 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$468
Medicare patients
32
Services billed
45

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala209$787,544
TivicayDolutegravir Sodium67$142,399
TrogarzoIbalizumab-Uiyk26$140,895
JulucaDolutegravir/Rilpivirine27$127,866
DescovyEmtricitabine/Tenofov Alafenam56$126,697
PrezcobixDarunavir/Cobicistat41$121,505
TriumeqAbacavir/Dolutegravir/Lamivudi16$53,497
MytesiCrofelemer13$33,772
DovatoDolutegravir Sodium/Lamivudine12$33,576
Isentress HdRaltegravir Potassium15$29,469
Maraviroc24$24,404
TrulicityDulaglutide29$24,156
FarxigaDapagliflozin Propanediol19$11,563
VascepaIcosapent Ethyl24$10,763
EliquisApixaban11$7,058

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$2,102$914,241265 claims
Viiv Healthcare CompanyTivicay, Juluca, Triumeq, Dovato$1,428$357,338122 claims
Theratechnologies Inc.Trogarzo$52$140,89526 claims
Johnson & JohnsonPrezcobix, Invokana$44$128,12353 claims
Napo Pharmaceuticals IncMytesi$15$33,77213 claims
MerckIsentress Hd$192$29,46915 claims
PfizerEliquis$17$7,05811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →